The Food and Drug Administration yesterday released a blueprint for educating health care providers that treat or monitor patients with pain under its forthcoming Risk Evaluation and Mitigation Strategy for companies that make opioid pain relievers. Accredited continuing education providers will use the blueprint to develop educational materials and activities for the REMS. FDA Commissioner Scott Gottlieb, M.D., said the revised blueprint includes more information on pain management and pharmacologic treatments for pain, including non-opioid pain relievers. In other news, FDA said it is working with manufacturers on safer packaging for Imodium A-D (loperamide) because some people addicted to opioids are taking the over-the-counter anti-diarrhea drug at dangerously high doses to manage withdrawal or achieve euphoric effects. Taking more than prescribed or listed on the label can cause severe heart rhythm problems or death.

Related News Articles

Headline
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…
Headline
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Headline
As the House Energy and Commerce Committee works to reauthorize key programs within the Substance Use-Disorder Prevention that Promotes Opioid Recovery and…
Headline
While counseling and other services are an important part of a comprehensive treatment plan for opioid use disorder, the provision of medication should not be…
Headline
AHA today launched an updated Opioid Stewardship Hub, featuring the latest tools and resources to help hospitals and health systems address the opioid epidemic…
Headline
The Food and Drug Administration last week required certain labeling updates for opioid pain medicines in an effort to reduce unnecessary prescribing and…